Rovi Pharmaceuticals Laboratories — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
EU sourced oral Femara® + Letrozole SIEThe study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.	Cancer	Phase 1	À vérifier	United States, Serbia, Spain	À vérifier
US-sourced oral Femara® + Letrozole SIEThe study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.	Cancer	Phase 1	À vérifier	United States, Serbia, Spain	À vérifier
US-sourced oral Femara® + Letrozole SIEThe study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.	Cancer	Phase 1	À vérifier	United States, Serbia, Spain	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
US-sourced oral Femara® + Letrozole SIE	Cancer	Phase 1	NCT07401381	SIE-1 — A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.